List price, manufacturer self-pay pricing, and what insurance really does — compared like with like.
At list price Zepbound is the cheaper of the two: about $1,060 a month against about $1,349 for Wegovy. But list price is close to meaningless, because almost nobody pays it.
Through the manufacturers' own cash-pay programs the two land much closer together — roughly $300 to $450 a month each, depending on dose. At the lowest starting doses Wegovy has at times been the cheaper of the two.
The reason online comparisons disagree so wildly is that three different numbers all get called "the price." Plenty of articles compare one drug's list price against the other's discounted price, which makes the gap look far bigger than it is.
Figures as of September 2026. Manufacturer programs change often — verify before you decide.
| How you pay | Zepbound (tirzepatide) | Wegovy (semaglutide) |
|---|---|---|
| List price | ~$1,060 / month | ~$1,349 / month |
| Manufacturer self-pay | ~$299–$449 / month via LillyDirect, by dose | ~$349 / month via NovoCare, less on starting doses |
| With insurance | Varies enormously. Many plans cover one and not the other, many require prior authorisation, and many exclude weight-loss drugs entirely. Medicare generally does not cover either for weight loss alone. | |
Reported self-pay figures differ between sources and have been revised more than once. Treat the ranges above as a guide and confirm current pricing with LillyDirect or NovoCare directly.
Cost is only half the question, and it is the half people research first.
Zepbound is tirzepatide, which acts on two hormone pathways — GLP-1 and GIP. Wegovy is semaglutide, which acts on GLP-1 alone. Different manufacturers, different molecules, different dosing schedules.
Which one is appropriate for you is a clinical decision, not a price comparison. A licensed provider weighs your health history, other medications and goals — and the cheaper drug is not automatically the right one.
It depends entirely on how you pay. At list price Zepbound is the cheaper of the two — roughly $1,060 a month against roughly $1,349 for Wegovy. But almost nobody pays list. Through the manufacturers' own self-pay programs the two land close together, in the $300–$450 range per month depending on your dose, and at the lowest doses Wegovy has at times been the cheaper option. Prices in this category change often, so check LillyDirect and NovoCare directly before deciding.
As of September 2026, Zepbound's list price is about $1,060 a month and Wegovy's is about $1,349 a month. List price is what the drug costs before insurance, discounts or manufacturer programs — it is the number almost nobody actually pays.
Eli Lilly's self-pay program prices Zepbound vials by dose — roughly $299 for 2.5 mg, $399 for 5 mg, and around $449 for the higher doses, after a price cut in December 2025. Confirm the current figures with LillyDirect, as the tiers have moved more than once.
Novo Nordisk's self-pay pharmacy has offered Wegovy in the region of $349 a month, with lower introductory pricing on the starting doses. Reported figures vary by source and have changed several times, so check NovoCare directly for what applies to your dose today.
Sometimes, and it varies enormously by plan. Many commercial plans cover one and not the other, many require prior authorisation or documented attempts at other treatment first, and a large number exclude weight-loss medication entirely. Medicare generally does not cover drugs prescribed solely for weight loss. Your plan's formulary is the only reliable answer.
Because three different numbers get called 'the price': the list price, the manufacturer's self-pay cash price, and your out-of-pocket cost after insurance. Articles often compare one drug's list price against another's discounted price, which makes the gap look far larger than it is. Compare like with like.
No. Zepbound is tirzepatide, which acts on two hormone pathways, GLP-1 and GIP. Wegovy is semaglutide, which acts on GLP-1 alone. They are different medications from different manufacturers, and which is appropriate for you is a decision for a licensed provider.
Red Lion Clinic is a telehealth practice. Licensed U.S. providers prescribe compounded semaglutide and tirzepatide — not Wegovy or Zepbound — at $299–$399 and $399–$599 per supply, with the provider's care, ongoing check-ins and free shipping included and no subscription. Details are on the cost page.
Compounded medications are not FDA-approved and are not evaluated by the FDA for safety and efficacy. Whether any treatment is appropriate for you is decided by a licensed provider.
Take the free assessment — a provider will recommend the right treatment for you.
Start your free assessment